NCT06804161

SGLT2 Inhibition for Cardiovascular Endpoint Reduction in Hypertension

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 3,000 (estimated)
• Sponsor: Prof. Dr. med. Ingo Eitel · Academic / Other
• Sex: All
• Age: 60 Years
• Healthy volunteers: Not accepted

Summary

Hypertension (HTN) is a leading cause of cardiovascular disease (CVD). Despite existing therapies, patients with HTN still face substantial risks, due to pre-existing and ongoing end-organ damage due, in part, to inadequate blood pressure (BP) control. SGLT2 inhibitors (SGLT2i) are recommended for both type-2 diabetes and heart failure to reduce morbidity and mortality. SGLT2i reduce BP and might also improve outcomes for HTN by reducing end-organ damage through diverse other actions. However, confirmation that SGLT2i are clinically useful for the management of HTN is required to change guidelines and clinical practice.

Conditions

• Atrial Hypertension

Interventions

Type	Name	Description
DRUG	SGLT2	10 mg
DRUG	Placebo	1 tablet

Timeline

• Start date: 2025-12-10
• Primary completion: 2032-05-30
• Completion: 2032-05-30
• First posted: 2025-02-03
• Last updated: 2025-12-22

Locations

1 site across 1 country: Germany